Adds a definition of "nicotine" and expands the definition of "tobacco products."
SB 1571 updates Oregon’s tobacco and inhalant-delivery-system laws by adding a standalone definition of “nicotine” and broadening the statutory definition of “tobacco products.” The bill makes clear that nicotine includes naturally or synthetically derived nicotine and its salts, complexes, alkaloids, and analogs. It also expands the products covered by the law to include oral nicotine pouches, nicotine lozenges, and other nicotine-containing products, while clarifying the treatment of FDA-approved cessation or therapeutic products and food items with only trace naturally occurring nicotine.
The bill also tightens retailer obligations and product standards for tobacco products and inhalant delivery systems. It requires visible warning notices for retailers, keeps the under-21 sales prohibition for inhalant delivery systems, and prohibits sale of inhalant delivery systems unless they are properly labeled, packaged in child-resistant packaging, and not packaged in a way that is attractive to minors. It also requires cigarettes to be sold only in sealed packages containing at least 20 cigarettes. The Oregon Health Authority is directed to adopt rules for the notice, labeling, and packaging requirements, and those rules must be consistent with applicable FDA regulations.
In practical terms, SB 1571 affects retailers, distributors, manufacturers, and consumers of vaping products, nicotine pouches, and other nicotine-based consumer products. It amends ORS 431A.175 and works alongside existing tobacco-control provisions, including age restrictions and packaging rules, to bring newer nicotine products more clearly within Oregon’s regulatory framework. The bill takes effect on the 91st day after adjournment of the 2026 regular session.
The overall sentiment around the bill appears favorable and relatively noncontroversial, as reflected by strong committee and floor votes in both chambers. The Senate passed the bill 26-1 and the House passed it 34-7, with committee votes also supporting the measure. The broad support suggests agreement on the need to update the law for modern nicotine products and youth-access protections.
The main points of contention likely center on the scope of regulation for vaping and nicotine products, especially the inclusion of oral nicotine pouches and other newer products in the tobacco-products definition, as well as packaging and labeling mandates for industry compliance. Any opposition appears limited, but the bill’s expansion of regulatory coverage and retailer obligations could raise concerns from affected businesses about compliance costs and the breadth of state oversight.
SB 1571 amends ORS 431A.175 to expand Oregon’s statutory definitions and enforcement rules for tobacco products and inhalant delivery systems. It broadens the legal reach of existing tobacco-control law to cover more nicotine products, including oral nicotine pouches and nicotine lozenges, and clarifies that nicotine includes synthetic and naturally derived forms. The bill also reinforces retailer notice requirements and product packaging, labeling, and age-restriction rules, with the Oregon Health Authority authorized to adopt implementing rules consistent with FDA standards.
The bill appears to have been received positively overall, with strong bipartisan support in committee and on the floor. It passed the Senate 26-1 and the House 34-7, indicating broad agreement on updating the law to address newer nicotine products and youth access concerns. The limited opposition suggests only modest disagreement, likely focused on regulatory scope rather than the bill’s core public-health purpose.
The most likely areas of contention are the bill’s expanded definition of tobacco products and the resulting regulatory burden on retailers and manufacturers of vaping and nicotine-pouch products. Businesses affected by labeling, child-resistant packaging, and “attractive to minors” restrictions may view the bill as increasing compliance costs or creating uncertainty in enforcement. Supporters, by contrast, appear to prioritize youth protection, clearer statutory definitions, and alignment with FDA-related product standards.